SAB Biotherapeutics Change in Accounts Receivable 2021-2025 | SABS

SAB Biotherapeutics change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

SAB Biotherapeutics Change in Accounts Receivable 2021-2025 | SABS

SAB Biotherapeutics change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.5B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$146.9B
Vertex Pharmaceuticals (VRTX)$100.7B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.1B
GSK (GSK)$80.2B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.8B
Argenex SE (ARGX)$40B
BioNTech SE (BNTX)$27.3B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.3B
Incyte (INCY)$17B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$11B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$7.9B